Toward Best Practices for Economic Evaluations of Tumor-Agnostic Therapies: A Review of Current Barriers and Solutions-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Toward Best Practices for Economic Evaluations of Tumor-Agnostic Therapies: A Review of Current Barriers and Solutions

Published:2023-11 Issue:11 Volume:26 Page:1608-1617
ISSN:1098-3015
Container-title:Value in Health
language:en
Short-container-title:Value in Health

Author:

Weymann Deirdre,Pollard Samantha,Lam Halina,Krebs Emanuel,Regier Dean A.

Funder

Roche Canada

AstraZeneca

Genome British Columbia

Roche

Terry Fox Research Institute

Genome Canada

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference73 articles.

1. Intra-tumour heterogeneity: a looking glass for cancer?;Marusyk;Nat Rev Cancer,2012

2. A history of cancer chemotherapy;DeVita;Cancer Res,2008

3. Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers;Laskin;Cold Spring Harb Mol Case Stud,2015

4. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials;Doebele;Lancet Oncol,2020

5. Indirect treatment comparison of larotrectinib versus entrectinib in treating patients with TRK gene fusion cancers;Garcia-Foncillas;Cancers,2022

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Next-generation sequencing in oncology: challenges in economic evaluations;Expert Review of Pharmacoeconomics & Outcomes Research;2024-08-11

2. “I Just Assumed This Was Already Being Done”: Canadian Patient Preferences for Enhanced Data Sharing for Precision Oncology;JCO Precision Oncology;2024-08

3. Healthcare decision-making for tumour-agnostic therapies in Europe: lessons learned;Drug Discovery Today;2024-07

4. Bayesian Hierarchical Modelling for Histology-Independent Time-to-Event Outcomes in the NICE Single Technology Appraisal of Pembrolizumab for Solid Tumours with MSI-H/dMMR: External Assessment Group Perspective;PharmacoEconomics;2024-05-07

5. Paving the path for implementation of clinical genomic sequencing globally: Are we ready?;Health Affairs Scholar;2024-04-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3